Research Suggests siRNAs Treat Macular Degeneration Via General Immune Response | GenomeWeb

NEW YORK (GenomeWeb News) – New research indicates that siRNA-based treatments for age-related macular degeneration do not specifically target key genes as previously believed. Instead, the authors say, they work by a more general mechanism, stimulating the immune system, which then attacks the offending cells.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.